Condition: Chronic Phase Ph+ Chronic Myeloid Leukemia · Sponsor: Il-Yang Pharm. Co., Ltd.
The goal of this observational study is to learn about the efficacy and safety profile when Radotinib dose redution is performed in Ph+ CML subjects. The main efficacy is checked by MMR rate by 12 months from IP treatment.
This description comes directly from the study's public registry record.
Na Yun Kim · 82-70-7165-7316 · nykim@ilyang.co.kr
Always discuss trial participation with your own doctor first.
| Hallym University Sacred Heart Hosptial | Anyang-si, Gyeonnggi-do, South Korea | Recruiting |
| Keimyung University Daegu Dongsan Hospital | Daegu, South Korea | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06665412